Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

Inclusion Criteria: * Male * Age 8 years to 17 years * Non-Ambulatory (unable to complete 10m run/walk under 10s) * Weight \</=100Kg * Diagnosis of DMD confirmed by at least one the following: * Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, or * Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, or * Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with DMD, with a typical clinical picture of DMD, or * Positive family history of DMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of DMD. * Cardiac ejection fraction \>55% on echocardiogram * Use of nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility has been discontinued at least 4 weeks prior to screening (daily multivitamin use is acceptable). * Glucocorticoid therapy, if used, must have a stable weight-based dose for at least 3 months prior to enrollment * Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor antagonists (e.g. spironolactone, eplerenone, etc.), and/or beta-blocker the…